PN,30601
SC,0001
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FTwo drugs to treat Alzheimer's disease
OL,8,Fhave been rejected for use on the NHS
OL,9,Fbecause their benefits are "too small"
OL,10,Fto justify their cost, the health
OL,11,Fspending watchdog has said.
OL,13,FThe National Institute for Health and
OL,14,FCare Excellence (Nice) is standing by
OL,15,Fits earlier decision to turn down
OL,16,Fdonanemab and lecanemab after
OL,17,Fconsidering new information submitted
OL,18,Fby manufacturers.
OL,26,@qD@\OUqD@fO]
OL,1,W~k4~sj5j5~s1G                    G1/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30602
SC,0002
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FCharities described the decision as
OL,8,F"disappointing" and a "painful
OL,9,Fsetback" for patients, while the firms
OL,10,FLilly, which makes donanemab, and
OL,11,FEisai, which makes lecanemab, said
OL,12,Fthey would appeal.
OL,14,FDonanemab and lecanemab are targeted
OL,15,Fantibody drugs that slow down the
OL,16,Fearly stages of Alzheimer's.
OL,18,FThey represent a huge step forward in
OL,19,Fresearch because they target a known
OL,20,Fcause of the disease, rather than just
OL,21,Ftreating symptoms.
OL,26,@pD@AOUpD@OO]pD@WOUqD@HO]
OL,1,W~k4~sj5j5~s1G                    G2/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30603
SC,0003
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FBoth drugs bind to amyloid, a protein
OL,8,Fwhich builds up in the brains of
OL,9,Fpeople living with Alzheimer's disease.
OL,11,FBy binding to amyloid, the drugs are
OL,12,Fdesigned to help clear the build-up
OL,13,Fand slow down cognitive decline.
OL,15,FPublishing its final draft guidance,
OL,16,FNice said the treatments have been
OL,17,Fshown to delay progression from mild
OL,18,Fto moderate Alzheimer's by four to six
OL,19,Fmonths.
OL,1,W~k4~sj5j5~s1G                    G3/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30604
SC,0004
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FBut it said the medicines cannot be
OL,8,Fprovided on the NHS because they are
OL,9,Fnot good value for money and "only
OL,10,Fprovide modest benefits at best".
OL,12,FLast year, NHS England published a
OL,13,Fbriefing paper suggesting the cost of
OL,14,Fbringing the drugs to the health
OL,15,Fservice could be #500 million to #1
OL,16,Fbillion per year.
OL,18,FProfessor Fiona Carragher, Alzheimer's
OL,19,FSociety's chief policy and research
OL,20,FOfficer, said the decision was
OL,21,F"disappointing".
OL,26,@qD@^OUrD@`O]}D@AOU}D@OO]
OL,1,W~k4~sj5j5~s1G                    G4/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30605
SC,0005
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FShe said: "There is no doubt that
OL,8,Ftoday's decision is a setback for
OL,9,Fpeople with Alzheimer's disease.
OL,11,F"It is highly disappointing that we
OL,12,Fare in a situation where treatments
OL,13,Fthat slow the progression of the
OL,14,Fcondition are not available on the NHS.
OL,16,F"The reality we're faced with is that
OL,17,Fthese treatments remain out of reach
OL,18,Fof both the NHS and most eligible
OL,19,Fpeople with Alzheimer's disease.
OL,26,@oD@KOUsD@AOUxD@AOU
OL,1,W~k4~sj5j5~s1G                    G5/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30606
SC,0006
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"In other diseases like cancer,
OL,8,Ftreatments have become more effective,
OL,9,Fsafer and cheaper over time. It's
OL,10,Fessential we see similar progress in
OL,11,Fdementia.
OL,13,F"The fact is, even if donanemab and
OL,14,Flecanemab were made available on the
OL,15,FNHS tomorrow, too many patients
OL,16,Fwouldn't be able to access them
OL,17,Fbecause the health system isn't ready
OL,18,Fto deliver them.
OL,20,F"The science is flying but the system
OL,21,Fis failing."
OL,26,@oD@AOUuD@AOU|D@AOU}D@LO]
OL,1,W~k4~sj5j5~s1G                    G6/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30607
SC,0007
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FShe said the Government must now
OL,8,Fcommit to "the long-term investment
OL,9,Fneeded to fundamentally change
OL,10,Fdementia diagnosis so that we are
OL,11,Fready for new treatments", including
OL,12,Fbringing in earlier diagnosis and
OL,13,Faccess to specialist diagnostic tests.
OL,15,FShe added: "We are heading towards a
OL,16,Ffuture where disease-slowing
OL,17,Ftreatments reduce the devastating
OL,18,Fimpact of dementia, and we cannot
OL,19,Fafford to delay preparing the NHS for
OL,20,Fthem."
OL,26,@pD@KOUsD@YO]wD@LOU|D@FO]
OL,1,W~k4~sj5j5~s1G                    G7/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30608
SC,0008
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FHilary Evans-Newton, chief executive
OL,8,Fof Alzheimer's Research UK, said:
OL,9,F"This rejection is a painful setback
OL,10,Ffor people affected by Alzheimer's `
OL,11,Fbut sadly not a surprising one.
OL,13,F"The drugs' modest benefits, combined
OL,14,Fwith the significant costs of
OL,15,Fdelivering them in the NHS, meant they
OL,16,Ffaced insurmountable challenges.
OL,26,@qD@AOUuD@AOU
OL,1,W~k4~sj5j5~s1G                    G8/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30609
SC,0009
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"People with early Alzheimer's in
OL,8,FEngland and Wales now face a long wait
OL,9,Ffor innovative new treatments as they
OL,10,Fwon't be able to access lecanemab or
OL,11,Fdonanemab unless they can afford to
OL,12,Fpay privately.
OL,14,F"This decision sends a troubling
OL,15,Fsignal to the life sciences sector `
OL,16,Fundermining confidence in the UK as a
OL,17,Fhome for research, innovation and
OL,18,Fclinical trials. That risks lasting
OL,19,Fdamage to both patients and the
OL,20,Feconomy.
OL,26,@oD@AOUvD@AOU
OL,1,W~k4~sj5j5~s1G                    G9/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30610
SC,0010
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"Nice's decision should ring alarm
OL,8,Fbells for a Government that, only a
OL,9,Fyear ago, pledged to make the UK a
OL,10,Fglobal leader in dementia treatments.
OL,12,F"With over 30 Alzheimer's drugs now in
OL,13,Flate-stage trials globally, momentum
OL,14,Fis building ` and more will enter
OL,15,Fregulatory systems in the years ahead.
OL,17,F"Without intervention from Government,
OL,18,Fpeople with Alzheimer's will continue
OL,19,Fto miss out ` not because science is
OL,20,Ffailing, but because the system is."
OL,26,@oD@AOUtD@AOUyD@AOU|D@dO]
OL,1,W~k4~sj5j5~s1G                   G10/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30611
SC,0011
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FHelen Knight, director of medicines
OL,8,Fevaluation at Nice, said: "While we
OL,9,Frecognise the hope these treatments
OL,10,Foffer, the evidence shows they only
OL,11,Fprovide modest benefits at best and
OL,12,Fsubstantial resources would be needed
OL,13,Fto provide them.
OL,26,@pD@[OU
OL,1,W~k4~sj5j5~s1G                   G11/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30612
SC,0012
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"The committee accepted that any
OL,8,Fslowing of the disease getting worse
OL,9,Fwould be meaningful for people with
OL,10,Fmild cognitive impairment or mild
OL,11,Fdementia caused by Alzheimer's disease
OL,12,Fand their carers because it could mean
OL,13,Fmore time socialising, driving and
OL,14,Fbeing independent, so needing less
OL,15,Fhelp day-to-day from family members.
OL,26,@oD@AOU
OL,1,W~k4~sj5j5~s1G                   G12/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30613
SC,0013
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"But the committee concluded the small
OL,8,Fbenefits to patients shown in the
OL,9,Fclinical trials and the lack of long-
OL,10,Fterm evidence of effectiveness
OL,11,Fbalanced with the substantial
OL,12,Fresources the NHS would need to commit
OL,13,Fto the treatments would be too great
OL,14,Fand could displace other essential
OL,15,Ftreatments and services that deliver
OL,16,Fsubstantial benefits to patients.
OL,26,@oD@AOU
OL,1,W~k4~sj5j5~s1G                   G13/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30614
SC,0014
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,F"We have done everything we possibly
OL,8,Fcan to try and achieve a positive
OL,9,Foutcome in our assessments of these
OL,10,Ftreatments, including providing an
OL,11,Fadditional opportunity for evidence to
OL,12,Fbe submitted.
OL,14,F"We realise today's news will be
OL,15,Fdisappointing for many, but we now
OL,16,Fneed to focus on the encouraging
OL,17,Fpipeline of new Alzheimer's drugs in
OL,18,Fdevelopment, a number of which are
OL,19,Falready earmarked for Nice evaluation."
OL,26,@oD@AOUvD@AOU{D@gO]
OL,1,W~k4~sj5j5~s1G                   G14/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30615
SC,0015
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FDrug firms and registered patient
OL,8,Fgroups now have until July 8 to appeal
OL,9,Fagainst the decision.
OL,11,FIn clinical trials, donanemab, which
OL,12,Fis given via a drip, has been shown to
OL,13,Fslow the rate at which memory and
OL,14,Fthinking get worse by more than 20%.
OL,16,FResults also suggest the drug leads to
OL,17,Fa 40% slowing in the decline of
OL,18,Feveryday activities such as driving,
OL,19,Fenjoying hobbies and managing money.
OL,1,W~k4~sj5j5~s1G                   G15/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30616
SC,0016
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FLecanemab ` also administered via drip
OL,8,F` has been shown to successfully
OL,9,Fremove protein build-up from the
OL,10,Fbrains of people living with early
OL,11,FAlzheimer's disease.
OL,13,FFor people taking lecanemab, this
OL,14,Fmeant the decline in their thinking
OL,15,Fand memory skills was slowed down by
OL,16,F27%.
OL,18,FIt also slowed down the decline in
OL,19,Fquality of life by up to 56%.
OL,1,W~k4~sj5j5~s1G                   G16/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30617
SC,0017
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FHowever, side-effects of the drugs can
OL,8,Fbe serious, including brain bleeds and
OL,9,Frisk of death.
OL,11,FA reformulation of lecanemab is being
OL,12,Fdeveloped so it can be administered
OL,13,Fsubcutaneously under the skin. Nice
OL,14,Fcould then review the drug in this
OL,15,Fform.
OL,17,FLilly said it would appeal the Nice
OL,18,Fdecision on the grounds it was
OL,19,Funreasonable based on the evidence
OL,20,Fsubmitted.
OL,1,W~k4~sj5j5~s1G                   G17/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30618
SC,0018
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FChris Stokes, president and general
OL,8,Fmanager of UK and Northern Europe at
OL,9,FLilly, said: "If the system can't
OL,10,Fdeliver scientific firsts to NHS
OL,11,Fpatients, it is broken.
OL,13,F"If the Government is to deliver on
OL,14,Fits goals to reduce lives lost to the
OL,15,Fbiggest killers and put Britain at the
OL,16,Fforefront of transforming treatment
OL,17,Ffor dementia, it must keep pace with
OL,18,Flicensed medical breakthroughs."
OL,26,@qD@NOUuD@AOUzD@`O]
OL,1,W~k4~sj5j5~s1G                   G18/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
PN,30619
SC,0019
CT,2,C
PS,c000
OL,0,        ECIMSBWebfax     F306A1750325321
OL,3,CAlzheimer's drugs rejected for NHS
OL,4,Cbecause benefits 'too small' to
OL,5,Cjustify cost
OL,7,FDr Jeremy Isaacs, national clinical
OL,8,Fdirector for dementia at NHS England,
OL,9,Fsaid: "NHS England has a dedicated
OL,10,Fteam preparing for the rollout of new
OL,11,FAlzheimer's treatments.
OL,13,F"There are several other Alzheimer's
OL,14,Ftreatments in development, and the NHS
OL,15,Fstands ready to offer patients access
OL,16,Fto new treatments as soon as they are
OL,17,Fdeemed by regulators to be clinically
OL,18,Fand cost effective."
OL,26,@qD@GOUuD@AOUzD@TO]
OL,1,W~k4~sj5j5~s1G                   G19/19
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,307,300,200,140,000,100
